[Comment] Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?

With the activity of checkpoint inhibitor monotherapy well documented in several diseases, attention has turned to developing effective combinations. Adding to the backbone of PD-1 inhibition, perhaps the most successful combination strategy to date has been with CTLA-4 inhibition. The combination of nivolumab (a PD-1 inhibitor) with ipilimumab (a CTLA-4 inhibitor) has been approved by the US Food and Drug Administration for the treatment of melanoma, renal cell carcinoma, and mismatch repair deficient or microsatellite unstable colorectal cancer.

Lascia un commento